Provided by Tiger Trade Technology Pte. Ltd.

Teva Pharmaceutical

37.34
+0.53001.44%
Post-market: 37.21-0.1287-0.34%19:53 EDT
Volume:4.30M
Turnover:160.85M
Market Cap:43.50B
PE:62.23
High:37.75
Open:36.79
Low:36.65
Close:36.81
52wk High:37.83
52wk Low:17.82
Shares:1.17B
Float Shares:1.09B
Volume Ratio:0.87
T/O Rate:0.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.6000
EPS(LYR):1.21
ROE:9.69%
ROA:5.13%
PB:5.61
PE(LYR):30.86

Loading ...

A Look At Teva (TEVA) Valuation After Strong Q1 2026 Earnings And Biosimilar Pipeline Progress

Simply Wall St.
·
Apr 30

Teva Upgraded to $45 Price Target on Strong Execution, Emalex Acquisition, and Growing Neurology Pipeline Upside

TIPRANKS
·
Apr 30

Teva price target raised to $45 from $42 at Truist

TIPRANKS
·
Apr 30

Stock Track | Teva Pharmaceutical Soars 12.02% Intraday on Strong Q1 Earnings Beat and Emalex Acquisition

Stock Track
·
Apr 29

Sector Update: Health Care

MT Newswires Live
·
Apr 29

Teva Pharmaceuticals Exec Says Co's Operations Remain Uninterrupted With No Material Impact on 2026 Guidance - Conf Call

THOMSON REUTERS
·
Apr 29

Teva Pharmaceuticals Exec Says It Is Difficult to Predict Whether There Will Be a Channel Drawdown Ahead of Price Changes Set to Take Effect in 2027

THOMSON REUTERS
·
Apr 29

Teva Pharmaceuticals Exec Says Co Is Seeing Nominal Increases in Some Transportation and Energy Costs Related to Middle East Conflict

THOMSON REUTERS
·
Apr 29

Teva Pharmaceuticals Exec Says Co Continue to Monitor Geopolitical Situation in the Middle East - Conf Call

THOMSON REUTERS
·
Apr 29

Teva reports Q1 EPS 53c, consensus 46c

TIPRANKS
·
Apr 29

Teva Pharmaceutical Beats First-Quarter Profit Estimates On Branded Drugs Demand

Reuters
·
Apr 29

GUIDANCE: (TEVA) Teva Pharmaceutical Industries Expects 2026 Non-GAAP EPS Range $1.91 - 2.11

MT Newswires Live
·
Apr 29

Stock Track | Teva Pharmaceutical Soars 5.41% in Pre-Market on Strong Q1 Earnings Beat and Emalex Acquisition

Stock Track
·
Apr 29

Teva Pharmaceutical Indus Q1 Adj. EPS $0.53 Beats $0.48 Estimate, Sales $3.982B Beat $3.810B Estimate

Benzinga Earnings
·
Apr 29

Press Release: Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution

Dow Jones
·
Apr 29

Teva to acquire Emalex Biosciences for $700M at closing

TIPRANKS
·
Apr 29

Notable companies reporting before tomorrow’s open

TIPRANKS
·
Apr 29

Teva put volume heavy and directionally bearish

TIPRANKS
·
Apr 29

Teva’s Home Ground Schizophrenia Push And What It Could Mean For Investors

Simply Wall St.
·
Apr 28

Teva Pharmaceutical Industries Ltd expected to post earnings of 46 cents a share - Earnings Preview

Reuters
·
Apr 27